LIN Songwen
Lin Songwen, PhD, is an associate professor and master supervisor. In 2011, he graduated from the School of Pharmacy of Peking University with a doctoral degree. From 2011 to 2013, he worked as a postdoctoral researcher at the joint workstation of Peking University and PKU Care Pharmaceutical R&D Center. In September 2015, he joined the Institute of Materia Medica of the Chinese Academy of Medical Sciences, and has successively served as assistant professor and associate professor. He focuses on the development of molecular targeted drugs and PROTACs technology, as well as targeted release of anti-tumor drugs for precise cancer treatment. Since 2011, more than 10 SCI papers have been published, and more than 10 invention patent applications have been filed.
Research field:
(1) Molecular targeted drugs.
(2) Proteolysis-Targeting Chimeras (PROTACs).
(3) Targeted release technology of anti-tumor drugs.
1. Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. J. Med. Chem. 2019, 62, 8873-8879.
2. Discovery and optimization of 2-amino-4-methylquinazoline derivatives as highly potent phosphatidylinositol 3-kinase inhibitors for cancer treatment. J. Med. Chem. 2018, 61, 6087–6109.
3. Design, synthesis and biological evaluation of quinazoline–phosphoramidate mustard conjugates as anticancer drugs. Eur. J. Med. Chem. 2017, 127, 442-458.
4. Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors. Bioorg. Med. Chem. 2018, 26, 637–646.
5. Discovery of a novel series of thienopyrimidine as highly potent and selective PI3K inhibitors. ACS Med. Chem. Lett. , 2015, 6, 434-438.
6. Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1 H )-one derivatives as potent PI3K/mTOR dual inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 790-793.
7. Synthesis and structure–activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3- d ]pyrimidine derivatives. Bioorg. Med. Chem. Lett. 2014, 24, 4538-4541.
8. Synthesis and analgesic evaluation of a series of proline-typed spiro cyclic quaternary ammoniums. Med. Chem. Res. 2014, 23, 862-869.
9. Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity. J. Control. Release. 2012, 160, 618-629.
10. Synthesis and structure-analgesic activity relationships of a novel series of monospirocyclopiperazinium salts (MSPZ). Bioorg. Med. Chem. Lett. 2011, 21, 940-943.
11. Discovery of New Thieno[2,3-d]pyrimidine and Thiazolo[5,4-d]pyrimidine Derivatives as Orally Active Phosphoinositide 3-Kinase Inhibitors. Bioorg. Med. Chem. 2021, 29, 115890.
12. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity. Cancer Lett. 2020, 495, 22–32.
13. Identification of novel thiazolo[5,4-b]pyridine derivatives as potent phosphoinositide 3-kinase inhibitors. Molecules. 2020, 25, 4630
14. Switching the site-selectivity of C–H activation in aryl sulfonamides containing strongly coordinating N -heterocycles. Chem. Sci. 2019, 10, 8744–8751.
15. Design, synthesis, and biological evaluation of 4-methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-kinases and histone deacetylases. J. Med. Chem. 2019, 62, 6992-7014
16. A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC. J. Drug Target. 2019, 27, 451-459
17. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer. J. Drug Target. 2018, 26, 920-930.
18. Ligand-free Cu-catalyzed O-arylation of aliphatic diols. RSC Adv. 2015, 5, 66104-66108.
